Rituximab resistance in ITP and beyond.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 01 05 2023
accepted: 10 07 2023
medline: 15 8 2023
pubmed: 14 8 2023
entrez: 14 8 2023
Statut: epublish

Résumé

The pathophysiology of immune thrombocytopenia (ITP) is complex and encompasses innate and adaptive immune responses, as well as megakaryocyte dysfunction. Rituximab is administered in relapsed cases and has the added benefit of inducing treatment-free remission in over 50% of patients. Nevertheless, the responses to this therapy are not long-lasting, and resistance development is frequent. B cells, T cells, and plasma cells play a role in developing resistance. To overcome this resistance, targeting these pathways through splenectomy and novel therapies that target FcγR pathway, FcRn, complement, B cells, plasma cells, and T cells can be useful. This review will summarize the pathogenetic mechanisms implicated in rituximab resistance and examine the potential therapeutic interventions to overcome it. This review will explore the efficacy of established therapies, as well as novel therapeutic approaches and agents currently in development.

Identifiants

pubmed: 37575230
doi: 10.3389/fimmu.2023.1215216
pmc: PMC10422042
doi:

Substances chimiques

Rituximab 4F4X42SYQ6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215216

Informations de copyright

Copyright © 2023 Xiao and Murakhovskaya.

Déclaration de conflit d'intérêts

IM has served as a consultant for Novartis, Janssen, Sanofi, Alexion, Apellis, Rigel. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Blood. 2016 Jan 7;127(1):17-28
pubmed: 26504182
Blood. 1987 Oct;70(4):1040-5
pubmed: 3651598
Blood. 2021 May 20;137(20):2736-2744
pubmed: 33827138
Br J Haematol. 2009 Apr;145(1):101-6
pubmed: 19208097
MAbs. 2014 Jul-Aug;6(4):991-9
pubmed: 24828435
Lancet. 2011 Jan 29;377(9763):393-402
pubmed: 20739054
Toxicol Sci. 2006 Jun;91(2):586-99
pubmed: 16517838
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Blood. 2001 Aug 15;98(4):952-7
pubmed: 11493438
Lancet. 2009 Feb 21;373(9664):641-8
pubmed: 19231632
Exp Ther Med. 2018 Sep;16(3):2471-2477
pubmed: 30186484
Rinsho Ketsueki. 2016 May;57(5):630-3
pubmed: 27263790
Haematologica. 2008 Jul;93(7):1113-5
pubmed: 18508788
Haematologica. 2020 Feb 27;106(1):250-254
pubmed: 32107327
Mol Cell Pediatr. 2021 Apr 29;8(1):5
pubmed: 33914175
Blood. 2018 Apr 5;131(14):1545-1555
pubmed: 29378696
Br J Haematol. 2015 Nov;171(4):625-30
pubmed: 26250874
Eur J Haematol. 2003 Jun;70(6):353-7
pubmed: 12756016
Crit Rev Immunol. 2018;38(1):17-62
pubmed: 29717662
Br J Haematol. 2019 Oct;187(2):e48-e51
pubmed: 31441030
Ann Hematol. 2016 Oct;95(11):1881-6
pubmed: 27525725
Br J Haematol. 2016 Jun;173(6):942-5
pubmed: 26305671
Pharmaceutics. 2022 May 11;14(5):
pubmed: 35631621
Br J Haematol. 2014 Jun;165(6):865-9
pubmed: 24725224
Haematologica. 2021 Sep 01;106(9):2449-2457
pubmed: 32817288
MAbs. 2013 Nov-Dec;5(6):826-37
pubmed: 23933992
Ann Hematol. 2023 Jan;102(1):245-247
pubmed: 36394581
Br J Haematol. 1985 Aug;60(4):723-33
pubmed: 4040770
J Immunol. 2021 Apr 1;206(7):1454-1468
pubmed: 33674445
Haematologica. 2021 Dec 01;106(12):3198-3201
pubmed: 34348453
Blood Adv. 2023 Mar 28;7(6):987-996
pubmed: 35973190
Blood Cells Mol Dis. 2023 Mar;99:102724
pubmed: 36669360
N Engl J Med. 2021 Sep 2;385(10):885-895
pubmed: 34469646
Ther Adv Hematol. 2019 May 09;10:2040620719837906
pubmed: 31156798
Blood. 2015 Jul 23;126(4):500-3
pubmed: 25972158
Eur J Haematol. 2015 Dec;95(6):532-7
pubmed: 25684257
Am J Hematol. 2018 Jul;93(7):E175-E177
pubmed: 29675829
Br J Haematol. 2004 Apr;125(2):232-9
pubmed: 15059147
J Autoimmun. 2013 Mar;41:182-7
pubmed: 23375848
Br J Haematol. 2015 Oct;171(2):247-253
pubmed: 26058843
J Int Med Res. 2023 Jan;51(1):3000605221149870
pubmed: 36650914
Clin Dev Immunol. 2013;2013:548085
pubmed: 24363761
Blood Adv. 2020 Sep 8;4(17):4136-4146
pubmed: 32886753
Thromb Res. 2007;120(2):187-93
pubmed: 17067661
Haematologica. 2009 Sep;94(9):1326-9
pubmed: 19734430
Am J Hematol. 2016 Sep;91(9):907-11
pubmed: 27220625
N Engl J Med. 2022 Apr 14;386(15):1421-1431
pubmed: 35417637
Oncogene. 2003 Oct 20;22(47):7359-68
pubmed: 14576843
N Engl J Med. 2020 Sep 17;383(12):1149-1155
pubmed: 32937047
Cancer Cell Int. 2019 Mar 15;19:59
pubmed: 30923461
Saudi J Biol Sci. 2019 Dec;26(8):2108-2112
pubmed: 31889803
Transplant Proc. 2003 May;35(3 Suppl):7S-14S
pubmed: 12742462
Br J Haematol. 2010 Apr;149(1):3-13
pubmed: 20151975
J Lab Clin Med. 1951 Jul;38(1):1-10
pubmed: 14850832
N Engl J Med. 2006 Oct 19;355(16):1672-81
pubmed: 17050891
N Engl J Med. 2013 Jan 3;368(1):90-2
pubmed: 23281998
Int J Hematol. 2018 Jan;107(1):69-74
pubmed: 28895035
Br J Haematol. 2014 Mar;164(6):900-2
pubmed: 24345005
Sci Transl Med. 2021 Apr 14;13(589):
pubmed: 33853929
Lupus. 2005;14 Suppl 1:s2-8
pubmed: 15803924
Br J Haematol. 2021 Sep;194(5):e84-e89
pubmed: 34046889
Cleve Clin J Med. 2021 Dec 2;88(12):664-668
pubmed: 34857604
Blood. 2014 Oct 30;124(18):2858-66
pubmed: 25232056
Blood. 2008 Aug 15;112(4):1078-84
pubmed: 18519809
Ann Rheum Dis. 2019 May;78(5):641-647
pubmed: 30826774
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35503254
Haematologica. 2008 Jun;93(6):930-3
pubmed: 18403395
J Thromb Thrombolysis. 2022 Aug;54(2):360-366
pubmed: 35471623
Drugs. 2016 Jan;76(1):155-8
pubmed: 26666417
Thromb Haemost. 2018 Oct;118(10):1752-1764
pubmed: 30235480
Blood. 2010 Nov 25;116(22):4639-45
pubmed: 20688957
Blood. 1994 Feb 15;83(4):1024-32
pubmed: 8111044
Blood Adv. 2020 Mar 10;4(5):815-818
pubmed: 32119735
Blood. 2006 Aug 1;108(3):943-6
pubmed: 16861348
Blood. 1999 Aug 1;94(3):909-13
pubmed: 10419881
Am J Hematol. 2018 Jul;93(7):921-930
pubmed: 29696684
Br J Haematol. 2018 Nov;183(3):479-490
pubmed: 30191972
Front Immunol. 2021 Mar 01;12:649441
pubmed: 33732266
N Engl J Med. 2010 Nov 11;363(20):1889-99
pubmed: 21067381
Blood Adv. 2019 Feb 12;3(3):447-460
pubmed: 30737226
Lancet Haematol. 2021 Apr;8(4):e289-e298
pubmed: 33770484
Blood. 1991 Nov 15;78(10):2619-25
pubmed: 1840468
Front Immunol. 2020 Jun 03;11:946
pubmed: 32655543
Blood. 2007 Oct 15;110(8):2924-30
pubmed: 17548576
J Int Med Res. 2020 Oct;48(10):300060520962348
pubmed: 33115308
Am J Hematol. 2020 Feb;95(2):178-187
pubmed: 31821591
Br J Haematol. 2007 Nov;139(4):605-11
pubmed: 17979946
Ther Clin Risk Manag. 2006 Sep;2(3):271-9
pubmed: 18360602
Blood. 2023 Jun 8;141(23):2867-2877
pubmed: 36893453
Nat Commun. 2015 Jul 17;6:7737
pubmed: 26185093
Int J Hematol. 2006 Apr;83(3):238-42
pubmed: 16720554
Ther Adv Hematol. 2022 May 14;13:20406207221097780
pubmed: 35585968
Arthritis Rheumatol. 2014 May;66(5):1153-64
pubmed: 24782179
Aust Prescr. 2016 Aug;39(4):131-134
pubmed: 27756976
Drugs. 2020 Aug;80(12):1259-1264
pubmed: 32729016
Br J Haematol. 2002 Jun;117(3):712-5
pubmed: 12028047
Blood. 2008 Aug 15;112(4):1147-50
pubmed: 18375792
Blood. 2004 Feb 15;103(4):1364-9
pubmed: 14576051
Immunopharmacology. 2000 May;47(2-3):119-25
pubmed: 10878286
Platelets. 2019;30(6):743-751
pubmed: 30296193
J Clin Invest. 2013 Jan;123(1):432-42
pubmed: 23241960
Front Med (Lausanne). 2020 Mar 31;7:110
pubmed: 32296709
Blood Coagul Fibrinolysis. 2016 Jun;27(4):431-5
pubmed: 26656905
Eur J Haematol. 2005 Jul;75(1):60-4
pubmed: 15946312
Lancet. 2022 Jan 8;399(10320):161-171
pubmed: 34861168
Am J Hematol. 2019 May;94(5):546-553
pubmed: 30784097
Res Pract Thromb Haemost. 2021 Aug 24;5(6):e12587
pubmed: 34466770
Ann Hematol. 2021 May;100(5):1351-1353
pubmed: 32405694
Curr Opin Rheumatol. 2016 May;28(3):251-8
pubmed: 27027812
Blood. 2021 Aug 26;138(8):674-688
pubmed: 33876188
Cells. 2022 Mar 16;11(6):
pubmed: 35326454
Am J Hematol. 2014 Jan;89(1):41-6
pubmed: 24038066
Br J Haematol. 2010 Feb;148(4):638-45
pubmed: 19925495
Hematology. 2009 Aug;14(4):224-6
pubmed: 19635186
Am J Hematol. 2019 Dec;94(12):1374-1381
pubmed: 31591739
Zhonghua Yi Xue Za Zhi. 2014 Oct 21;94(38):3011-3
pubmed: 25547706
J Exp Med. 2014 Jan 13;211(1):45-56
pubmed: 24367004
Blood. 1996 May 15;87(10):4245-54
pubmed: 8639783
Am J Hematol. 2006 Jan;81(1):19-25
pubmed: 16369979
Immunotherapy. 2020 Dec;12(18):1325-1340
pubmed: 33023353
Ann Hematol. 2006 Jun;85(6):400-6
pubmed: 16550390
Ther Adv Hematol. 2021 Nov 12;12:20406207211046428
pubmed: 34795889
Br J Haematol. 2022 May;197(3):359-366
pubmed: 35179784
Blood. 2014 Nov 20;124(22):3228-36
pubmed: 25293768
Nat Med. 2003 Sep;9(9):1123-4
pubmed: 12937414
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Br J Haematol. 2001 Jul;114(1):121-5
pubmed: 11472356
Haematologica. 2019 Jun;104(6):1112-1123
pubmed: 31073079
Nat Med. 2015 Jan;21(1):47-54
pubmed: 25485912
Blood. 2012 Jun 21;119(25):5989-95
pubmed: 22566601
Hematology. 2012 Sep;17(5):283-90
pubmed: 22971534
Mayo Clin Proc. 2019 Nov;94(11):2199-2208
pubmed: 31685150
Am J Hematol. 2005 Apr;78(4):275-80
pubmed: 15795920
Platelets. 2022 Jul 4;33(5):801-806
pubmed: 35132908
Lancet. 2008 Feb 2;371(9610):395-403
pubmed: 18242413
Acta Pharmacol Sin. 2005 May;26(5):598-602
pubmed: 15842780
Blood. 2013 Oct 3;122(14):2477-86
pubmed: 23963041
Curr Opin Hematol. 2007 Nov;14(6):642-6
pubmed: 17898569
Sci Adv. 2019 Dec 18;5(12):eaax9586
pubmed: 31897428
Blood. 2010 Jan 7;115(1):29-31
pubmed: 19897578
Am J Ther. 2018 Mar/Apr;25(2):e270-e272
pubmed: 29293474
Eur J Haematol. 2012 Feb;88(2):167-74
pubmed: 21985182
J Pharmacol Pharmacother. 2011 Oct;2(4):317-9
pubmed: 22025872
Am J Hematol. 2012 Feb;87(2):206-8
pubmed: 22139961
Expert Rev Clin Immunol. 2016 Jul;12(7):763-73
pubmed: 26864273
Drugs. 2021 Jul;81(11):1285-1305
pubmed: 34160821
Immunotherapy. 2015;7(9):1011-22
pubmed: 26325610
Haematologica. 2015 May;100(5):623-32
pubmed: 25682608
Sci Rep. 2016 Jun 20;6:27445
pubmed: 27321376
Clin Exp Immunol. 2020 Sep;201(3):258-265
pubmed: 32515487
Front Immunol. 2021 Feb 17;12:630693
pubmed: 33679776
J Hematol Oncol. 2021 Feb 25;14(1):37
pubmed: 33632264
Int J Clin Exp Pathol. 2015 Nov 01;8(11):15429-32
pubmed: 26823908
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
Clin Case Rep. 2015 Jun;3(6):337-41
pubmed: 26185623
MAbs. 2011 Sep-Oct;3(5):422-30
pubmed: 22048693
Am J Hematol. 2007 Sep;82(9):846-8
pubmed: 17506067
N Engl J Med. 2020 Aug 13;383(7):650-663
pubmed: 32786190
Eur J Haematol. 2017 Apr;98(4):371-377
pubmed: 27981682
Platelets. 2011;22(2):153-6
pubmed: 21142405
J Med Chem. 2022 Apr 14;65(7):5300-5316
pubmed: 35302767
Front Cardiovasc Med. 2021 Sep 24;8:749022
pubmed: 34631841

Auteurs

Zhengrui Xiao (Z)

Division of Hematology, Department of Hematology-Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, United States.

Irina Murakhovskaya (I)

Division of Hematology, Department of Hematology-Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York City, NY, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH